logo

Urovant Sciences Ltd. (UROV)



Trade UROV now with
  Date
  Headline
6/18/2020 4:15:40 PM Urovant Sciences Q4 Loss/share $1.68 Vs. Loss $0.96 Year Ago
6/2/2020 8:09:25 AM Urovant Sciences Appoints Walt Johnston As SVP Of Commercial, Kenton Stewart As SVP Of Market Access
5/27/2020 8:07:47 AM Urovant Sciences Appoints Jim Hindman To Board
5/14/2020 8:12:22 AM Urovant Sciences Presents Positive Clinical Efficacy & Safety Data On Vibegron At Virtual AUA Annual Meeting
3/23/2020 4:10:59 PM Urovant Sciences Appoints James Robinson As President And CEO
3/2/2020 8:07:14 AM Urovant Sciences Announces Publication Of Phase 3 EMPOWUR Trial Results
2/4/2020 8:17:32 AM Urovant Sciences Reports Publication Of Safety And efficacy Results Of URO-902
12/30/2019 4:45:27 PM Urovant Sciences Announces Submission Of New Drug Application For Vibegron For Treatment Of Overactive Bladder
12/30/2019 8:08:03 AM Urovant Sciences Enters Into $300 Mln Term Loan Agreement With Sumitomo Dainippon Pharma
12/23/2019 8:05:53 AM Urovant Sciences Initiates Patient Enrollment In Phase 2a Study Of URO-902
10/31/2019 9:33:10 AM Urovant Sciences Announces Creation Of A Broad Sumitomo Dainippon-Roivant Strategic Alliance
9/6/2019 9:12:01 AM Roivant Sciences, Sumitomo Dainippon Pharma To Create Broad Strategic Alliance
6/13/2019 4:06:56 PM Urovant Sciences Q4 Loss/share $0.96 Vs. Loss $0.95 Year Ago
3/19/2019 8:08:04 AM Urovant Sciences Announces Positive Topline Results From Pivotal Phase 3 EMPOWUR Study Of Vibegron
11/12/2018 4:07:09 PM Urovant Sciences Q2 Loss/share $1.23 Vs. Loss $0.25 Year Ago
11/8/2018 8:05:56 AM Urovant Sciences Completes Patient Enrollment In Phase 3 Pivotal Trial Studying Vibegron For Overactive Bladder